BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31010620)

  • 21. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors.
    van Kempen PM; Noorlag R; Swartz JE; Bovenschen N; Braunius WW; Vermeulen JF; Van Cann EM; Grolman W; Willems SM
    Cancer Immunol Immunother; 2016 May; 65(5):575-85. PubMed ID: 26993499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
    Brcic I; Gallob M; Schwantzer G; Zrnc T; Weiland T; Thurnher D; Wolf A; Brcic L
    Oral Oncol; 2020 Jul; 106():104719. PubMed ID: 32335324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
    de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
    Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
    Fukushima Y; Someya M; Nakata K; Hori M; Kitagawa M; Hasegawa T; Tsuchiya T; Gocho T; Ikeda H; Hirohashi Y; Torigoe T; Sugita S; Hasegawa T; Himi T; Sakata KI
    Radiother Oncol; 2018 Nov; 129(2):409-414. PubMed ID: 30249348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.
    Hong AM; Vilain RE; Romanes S; Yang J; Smith E; Jones D; Scolyer RA; Lee CS; Zhang M; Rose B
    Oncotarget; 2016 Nov; 7(47):77010-77020. PubMed ID: 27776338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
    Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
    Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
    Qin Y; Luan J; Zhou X; Li Y
    Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
    Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
    J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ki67 Expression has Prognostic Significance in Relation to Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma.
    Liu J; Zhang M; Rose B; Veillard AS; Jones D; Zhang X; Soon Lee C; Milross C; Hong A
    Ann Surg Oncol; 2015; 22(6):1893-900. PubMed ID: 25404475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relevance of the lymph node ratio as predictor of prognosis is higher in HPV-negative than in HPV-positive oropharyngeal squamous cell carcinoma.
    Meyer MF; Meinrath J; Seehawer J; Lechner A; Odenthal M; Quaas A; Semrau R; Huebbers CU; Marnitz S; Büttner R; Beutner D
    Clin Otolaryngol; 2018 Feb; 43(1):192-198. PubMed ID: 28714274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
    Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
    Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC.
    Sanford NN; Hwang WL; Pike LRG; Lam AC; Royce TJ; Mahal BA
    Oral Oncol; 2019 Nov; 98():28-34. PubMed ID: 31536843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era.
    Keane FK; Chen YH; Neville BA; Tishler RB; Schoenfeld JD; Catalano PJ; Margalit DN
    Cancer; 2015 Aug; 121(15):2594-602. PubMed ID: 25873094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.
    Martin-Gomez L; Fulp WJ; Schell MJ; Sirak B; Abrahamsen M; Isaacs-Soriano KA; Lorincz A; Wenig B; Chung CH; Caudell JJ; Giuliano AR
    Oral Oncol; 2019 May; 92():85-91. PubMed ID: 31010629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17(+) cell frequency.
    Punt S; Dronkers EA; Welters MJ; Goedemans R; Koljenović S; Bloemena E; Snijders PJ; Gorter A; van der Burg SH; Baatenburg de Jong RJ; Jordanova ES
    Cancer Immunol Immunother; 2016 Apr; 65(4):393-403. PubMed ID: 26899388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.